Industry News

Mylab parter with Serum institute India to scale up production of COVID-19 testing kit

  • Posted on: 3 April 2020
  • By: admin

In order to scale up the operations and escalate faster delivery of testing kits for the novel coronavirus (Covid-19), Pune-based molecular diagnostics company Mylab Discovery Solutions Pvt Ltd has partnered with Serum India’s CEO Adar Poonawalla and Abhijit Pawar, Chairman of APG. Funds invested will be used for scaling production of COVID-19 testing kits and expansion of molecular diagnostic solutions.

Dr. Reddy's Laboratories Issues Voluntary Nationwide Recall of Phytonadione Injectable Emulsion USP, 10 mg/mL Single-Dose Ampules Due To Ampules Breaking And Shattering Upon Opening

  • Posted on: 1 April 2020
  • By: Shalini.Sharma

Dr. Reddy’s Laboratories Ltd. (along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that it is voluntarily recalling four lots (ACB902, ACB903, ACB904, ACB905) of Phytonadione Injectable Emulsion USP, 10 mg/mL, Single-Dose Ampules to the hospital level. The product is being recalled due to product complaints received due to ampules breaking and shattering, upon opening, during compounding.

Daiichi Sankyo and Kitasato Pharma to terminate sales agreement of Influenza HA vaccine

  • Posted on: 28 March 2020
  • By: admin

Daiichi Sankyo Company, Limited and Kitasato Pharmaceutical Industry Co., Ltd. (hereinafter, “ Kitasato Pharmaceutical Industry”) announced the termination of their cooperative sales agreement for Influenza HA Vaccine “Daiichi Sankyo” 1 mL and Influenza HA Vaccine Syringe “Daiichi Sankyo” 0.25 mL and 0.5 mL on March 31, 2020 in Japan.

AstraZeneca collaborate with Silence Therapeutics to discover, develop and commercialise small siRNA

  • Posted on: 27 March 2020
  • By: admin

AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases.

Novartis, Teva and Mylan to supply around 200 millions of doses of antimalarial drugs to fight against corona virus

  • Posted on: 21 March 2020
  • By: PharmaTutor News

Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Also, there are few results suggested that Hydroxychloroquine is effective against COVID-19. Three pharma giants Novartis, Mylan and Teva Pharma announced that they will donate millions of doses of hydroxychloroquine to support the global COVID-19 pandemic response.